Our Projects
Our goal is to collaborate with veterinarians, researchers, and pharmaceutical companies to bring cutting-edge treatments to market, improving the lives of pets and livestock alike. By leveraging our experience in regulatory compliance, data integrity, and patient care, PRG ensures the same rigorous standards are applied to veterinary research, paving the way for breakthroughs in animal healthcare.
Currently Enrolling Trials
-
REV-001 is a new oral chew that is currently being studied on canines for chronic pain related issues. REV-001 is being developed to provide an alternative therapy that reduces toxicity complications typically seen with long-term use of opioids.
-
REV-002 is an oral suspension in development for the treatment of canine separation anxiety disorder.
-
REV-003 is an oral suspension in development for the treatment of canine chronic pain conditions. REV-003 is being developed to provide an alternative therapy that reduces toxicity complications typically seen with long-term use of opioids.
-
This study will require dogs to be hospitalized for 5 hours, all study appointments will be scheduled for early morning drop off.
To be eligible to participate canines must be:
Client-owned dogs, either sex and reproductive status, aged 12 months and older.
Diagnosed with melanoma with validation.
No known or suspected medical condition that could interfere with the treatment outcome and/or effectiveness.
No planned procedures involving general anesthesia for the dog during the study.
Has not previously received corticosteroids, chemotherapy, immunotherapy or radiation.
Free physical exam, bloodwork and chemotherapy will be provided.